Role of the E2F1-p19ARF-p53 Pathway in Ischemic Acute Renal Failure

2005 ◽  
Vol 101 (2) ◽  
pp. p27-p34 ◽  
Author(s):  
Hiroyuki Tanaka ◽  
Yoshio Terada ◽  
Tomokazu Okado ◽  
Seiji Inoshita ◽  
Michio Kuwahara ◽  
...  
1987 ◽  
Vol 32 (3) ◽  
pp. 313-321 ◽  
Author(s):  
Robert W. Schrier ◽  
Patricia E. Arnold ◽  
Vicki J. Van Putten ◽  
Thomas J. Burke

2007 ◽  
Vol 49 (3) ◽  
pp. 154-160 ◽  
Author(s):  
Junji Yamashita ◽  
Mamoru Ohkita ◽  
Masanori Takaoka ◽  
Yoshiaki Kaneshiro ◽  
Takato Matsuo ◽  
...  

1994 ◽  
Vol 267 (6) ◽  
pp. F1052-F1058 ◽  
Author(s):  
H. Rabb ◽  
C. C. Mendiola ◽  
J. Dietz ◽  
S. R. Saba ◽  
T. B. Issekutz ◽  
...  

Leukocytes, particularly neutrophils, have been implicated in ischemic-reperfusion organ injury (IRI). However, their role in kidney IRI is controversial. Leukocytes express the adhesion molecules CD11/CD18 on their surface, which mediate many functions that can lead to tissue damage. To determine the role of CD11a and CD11b in IRI in the kidney, uninephrectomized Sprague-Dawley rats were pretreated with monoclonal antibodies (MAbs) directed against CD11a and CD11b or control MAbs. The serum creatinine (SCr), complete blood count, and kidney histopathological damage scores (PDS) (scale: 0-4) were assessed prior to and 24 h after 60 min of ischemia. Mean SCr 24 h after ischemia was significantly decreased in the anti-CD11a- and -CD11b-treated group compared with the control MAb-treated group (2.5 +/- 0.3 mg/dl vs. 3.4 +/- 0.2 mg/dl, P <0.05). PDS were also reduced in the CD11a and CD11b group compared with controls (2.7 +/- 0.2 vs. 3.5 +/- 0.1, P < 0.001). These data show that the CD11/CD18 leukocyte adhesion pathway plays a role in mediating ischemic acute renal failure in rats.


1983 ◽  
Vol 7 (1-2) ◽  
pp. 49-61 ◽  
Author(s):  
Thomas J. Burke ◽  
Douglas R. Wilson ◽  
Moshe Levi ◽  
Joel A. Gordon ◽  
Patricia E. Arnold ◽  
...  

2002 ◽  
Vol 40 (4) ◽  
pp. 586-593 ◽  
Author(s):  
Masahiro Nishida ◽  
Miyuki Ieshima ◽  
Fumiko Konishi ◽  
Junji Yamashita ◽  
Masanori Takaoka ◽  
...  

2008 ◽  
Vol 294 (1) ◽  
pp. F264-F271 ◽  
Author(s):  
Dong-Jin Oh ◽  
Belda Dursun ◽  
Zhibin He ◽  
Lawrence Lu ◽  
Thomas S. Hoke ◽  
...  

Fractalkine (CX3CL1) is expressed on injured endothelial cells and is a potent chemoattractant and adhesion molecule for macrophages carrying the fractalkine receptor (CX3CR1). The aim of this study was to investigate the role of CX3CL1, and its ligand CX3CR1, in ischemic acute renal failure (ARF) in mice. On immunoblotting, CX3CL1 protein expression in the kidney increased markedly in ischemic ARF. On immunofluorescence staining, the intensity of CX3CL1 staining in blood vessels was significantly more prominent in ischemic ARF compared with controls. A specific anti-CX3CR1 antibody (25 μg ip 1 h before induction of ischemia) was functionally and histologically protective against ischemic ARF. CX3CR1 is predominantly expressed on macrophages. Macrophage infiltration in the kidney in ischemic ARF was significantly decreased after anti-CX3CR1 antibody treatment. To determine the role of macrophages in ischemic ARF, macrophages in the kidney were depleted using liposomal-encapsulated clodronate (LEC). LEC resulted in significant functional and histological protection against ischemic ARF. In summary, in ischemic ARF, 1) there is upregulation of CX3CL1 protein in the kidney, specifically in blood vessels; 2) CX3CR1 inhibition using a specific antibody is partially protective and is associated with reduced macrophage infiltration in the kidney; and 3) macrophage depletion in the kidney is protective.


2003 ◽  
Vol 481 (2-3) ◽  
pp. 241-248 ◽  
Author(s):  
Toshihide Fujii ◽  
Hayato Kurata ◽  
Masanori Takaoka ◽  
Tomoko Muraoka ◽  
Yoshihide Fujisawa ◽  
...  

Renal Failure ◽  
1994 ◽  
Vol 16 (5) ◽  
pp. 555-569 ◽  
Author(s):  
Lothar Schramm ◽  
Ekkehart Heidbreder ◽  
Anselm Schmitt ◽  
Kathrin Kartenbender ◽  
Josef Zimmermann ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document